DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/scjzgs/global_womens) has announced the addition of the "Global Women's Health Market 2014-2018" report to their offering.
The Global Women's Health market will grow at a CAGR of 3.52 percent over the period 2013-2018.
Women experience physiological and emotional issues during different phases of their life cycle due to hormonal changes. Women's health is especially referred to where reproductive health is involved. According to the Society for Women's Health Research in the US, issues specific to the human female anatomy are defined as women's health. The biological mechanisms influence the clinical course of diseases and disorders differently in women when compared to men. Some of the main women's health disorders include infertility, menopause, endometriosis and polycystic ovarian syndrome as well as urological disorders and cancers such as breast cancer, cervical cancer, endometrial cancer, and ovarian cancer. In addition, contraception plays an important role in women's health for many reasons, so this too is also categorized under women's health.
To calculate the market size, the report considers revenue generated from the sales of various products used for the wellbeing of women, which are listed below based on their application segment:
- Postmenopausal Osteoporosis (Drugs)
- Hormonal Contraceptives (Drugs and Devices)
- Menopause (Drugs)
- Infertility (Drugs)
- Endometriosis (Drugs)
- Polycystic Ovary Syndrome (Drugs)
The report, the Global Women's Health Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA, and the APAC regions; it also covers the Global Women's Health market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
- Actavis plc
- Bayer AG
- Eli Lilly and Co.
- Merck & Co.
- Pfizer Inc.
According to the report, the growth of the Global Women's Health market is curtailed by some serious challenges. One of the main challenges is the patent expiry of major blockbuster drugs during the forecast period. Some of the patent expiries of top leading products include Bayer's Mirena and Yaz, Eli Lilly's Evista, and F. Hoffmann-La Roche's Boniva.
For more information visit http://www.researchandmarkets.com/research/scjzgs/global_womens